Table 3.

Factors Associated With H pylori Resistance to Clarithromycin, Metronidazole, and Levofloxacin in Male Patients in Multivariate Analysis

	Clarithromycin resistance	Metronidazole resistance	Levofloxacin resistance	Any resistance
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
Age (y)
≥60 (vs <60)	2.16 (0.67–6.99)	0.74 (0.26–2.10)	2.34 (0.87–6.28)	1.04 (0.44–2.48)
Race/ethnic
Black (vs white)	1.10 (0.32–3.83)	0.89 (0.27–2.95)	1.80 (0.62–5.27)	2.18 (0.81–5.83)
Hispanic (vs white)	1.47 (0.35–6.11)	1.87 (0.46–7.66)	2.48 (0.65–9.52)	1.78 (0.52–6.07)
Isolated year
2011–2013 (vs 2009–2013)	2.57 (0.83–8.00)	0.69 (0.23–2.03)	1.89 (0.72–4.93)	2.52 (1.06–5.97)
Prior treatment of H pylori
Yes (vs no)	11.37 (1.79–72.21)	4.64 (0.86–24.92)	3.83 (0.60–24.36)	—
Household income ($)
>25,000 (vs ≤25,000)	—	—	3.15 (1.21–8.25)	2.61 (1.10–6.18)
Drinking status
Former drinker (vs never drank)	—	0.12 (0.02–0.65)	—	—
Current drinker (vs never drank)	—	0.19 (0.04–0.94)	—	—
Prior use of macrolides
Yes (vs no)	—	—	—	3.92 (1.39–11.07)
Prior use of fluoroquinolones
Yes (vs no)	—	—	3.49 (1.30–9.36)	—